Eukles Asset Management Sells 1,334 Shares of Masimo Co. (NASDAQ:MASI)

Eukles Asset Management lessened its holdings in shares of Masimo Co. (NASDAQ:MASI) by 19.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,670 shares of the medical equipment provider’s stock after selling 1,334 shares during the period. Eukles Asset Management’s holdings in Masimo were worth $937,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares in the last quarter. Inspire Investing LLC purchased a new position in shares of Masimo during the third quarter worth approximately $395,000. Exchange Traded Concepts LLC raised its stake in shares of Masimo by 17.4% during the third quarter. Exchange Traded Concepts LLC now owns 12,550 shares of the medical equipment provider’s stock worth $1,673,000 after acquiring an additional 1,862 shares in the last quarter. NBC Securities Inc. grew its holdings in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the last quarter. Finally, Kapitalo Investimentos Ltda bought a new position in shares of Masimo in the third quarter worth approximately $242,000. Institutional investors own 85.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wells Fargo & Company raised their target price on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Raymond James raised their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Stock Performance

NASDAQ:MASI opened at $176.16 on Monday. The stock has a market cap of $9.43 billion, a P/E ratio of 121.49 and a beta of 1.02. The firm’s fifty day simple moving average is $171.63 and its 200 day simple moving average is $147.10. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $183.14. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.